Divergent Roles of Federal and Industry Sponsors in US Cancer Clinical Trials: Insights from 2008 to 2024
This study quantifies how federal and industry sponsorship differ in US cancer clinical trials, highlighting complementary focuses: industry emphasizes single-agent drug therapies, while federal trials prioritize multimodality regimens, rare cancers, pediatric populations, and supportive care.
